Overview
Epimedium Prenylflavonoid (EP) Extract for Osteoporosis and Cardiovascular Disease
Status:
Unknown status
Unknown status
Trial end date:
2017-10-01
2017-10-01
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
The primary objective of the trial is to develop Epimedium Prenylflavonoid (EP) extract as a pharmaceutical-quality intervention for post-menopausal osteoporosis and cardiovascular disease. There will be 3 cohorts of 10 healthy men each for the Phase 1 study. In each cohort, 8 men will receive the Epimedium capsules and 2 men will received the matched controls.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
National University Hospital, Singapore
Criteria
Inclusion Criteria:- Healthy men.
Exclusion Criteria:
- Hepatitis B patients